News & Updates

Show Multimedia Only
Use of biomarkers, biologics ups success rate of clinical trials in gastric cancer

Use of biomarkers, biologics ups success rate of clinical trials in gastric cancer

01 Mar 2023

Success rates of clinical trials in gastric cancer tend to improve with the use of implementing biomarkers, receptor-targeted therapies, and biologics in clinical development, suggests a recent study.

Use of biomarkers, biologics ups success rate of clinical trials in gastric cancer

01 Mar 2023
Statin therapy reduces major vascular events after stroke

Statin therapy reduces major vascular events after stroke

01 Mar 2023
Doxycycline, meningo vax reduce STI incidence among MSM on PrEP

Doxycycline, meningo vax reduce STI incidence among MSM on PrEP

28 Feb 2023 byStephen Padilla

Use of doxycycline as postexposure prophylaxis (PEP) results in a significant decrease in the incidence of Chlamydia trachomatis (CT) and syphilis and demonstrates a significant impact on the incidence of Neisseria gonorrhoeae (GC), reports a study presented at the 30th Conference on Retroviruses and Opportunistic Infections (CROI). Meningococcal B vaccine also helps lower the incidence of GC.

Doxycycline, meningo vax reduce STI incidence among MSM on PrEP

28 Feb 2023
PrEP use tied to ‘stable’ STI incidence, sexual behaviour among MSM

PrEP use tied to ‘stable’ STI incidence, sexual behaviour among MSM

27 Feb 2023 byStephen Padilla

The incidence of sexually transmitted infection (STI) over the first 4 years of pre-exposure prophylaxis (PrEP) use remains high and stable, but the incidence of chlamydia and gonorrhea has slightly decreased among daily PrEP users, as shown in a study presented at the 30th Conference on Retroviruses and Opportunistic Infections (CROI).

PrEP use tied to ‘stable’ STI incidence, sexual behaviour among MSM

27 Feb 2023